Morphic Holding, discover and develop a pipeline of potentially first-in-class oral small-molecule integrin therapeutics. Filed for an IPO with NASDAQ under the symbol “MORF”.
Morphic Holding offering 5.0 million shares at a price range of $14.00 – $16.00.
Manager and Joint Managers- Jefferies, Cowen, BMO Capital Markets and Wells Fargo Securities. The IPO is expected to price on June 27, 2019.
Morphic Holding is Biopharmaceutical Company applying our proprietary insights into integrins to discover and develop a pipeline of potentially first-in-class oral small-molecule integrin therapeutics. Integrins are a target class with multiple approved injectable blockbuster drugs for the treatment of serious chronic diseases, including autoimmune, cardiovascular and metabolic diseases, fibrosis and cancer. To date, no oral small-molecule integrin therapies have been approved by the U.S. Food and Drug Administration, or FDA. Despite significant unsuccessful efforts, we believe tremendous untapped potential remains for us to develop oral integrin therapies.
The IPO is expected to trade on NASDAQ on June 27, 2019
Featured photo credit to internet